Meta-analysis of trials in 3,281 patients with relapsed/refractory blood cancers: CAR T-cell pooled response rates were 89% in myeloma, 76% in high-grade lymphoma and 78% in leukaemia, but any-grade CRS (89%, 46%, 85%) and grade ≥3 neutropenia were common.
Meta-analysisn = 3,281
Filippatos et al. Chimeric Antigen Receptor T-Cells (CAR T-Cells) in Hematological Malignancies: A Systematic Review and Meta-Analysis of Proportions From Clinical Trials